Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 2, 2013, Pages 139-147

  Welsh, Allison W ^a   Harigopal, Malini ^a   Wimberly, Hallie ^a   Prasad, Manju ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; companion diagnostic; endocrine therapy; estrogen receptor; immunohistochemistry; quantitative immunofluorescence

Indexed keywords

ESTROGEN RECEPTOR BETA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1D5; MONOCLONAL ANTIBODY SP1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RABBIT; RETROSPECTIVE STUDY; SIGNAL NOISE RATIO; STANDARDIZATION;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN RECEPTOR BETA; FALSE NEGATIVE REACTIONS; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; RABBITS; RETROSPECTIVE STUDIES; SIGNAL-TO-NOISE RATIO; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874933316     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31825d73b2     Document Type: Article

References (32)

1. Hahnel R, Woodings T, Vivian AB. Prognostic value of estrogen receptors in primary breast cancer. Cancer. 1979;44:671-675. (Pubitemid 10220153)
2. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168. (Pubitemid 28144151)
3. Chia SK, Wolff AC. With maturity comes confidence: EBCTCG tamoxifen update. Lancet. 2011;378:747-749.
4. Clark GM, McGuire WL, Hubay CA, et al. The importance of estrogen and progesterone receptor in primary breast cancer. Prog Clin Biol Res. 1983;132E:183-190.
5. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, alone or in combination trial. J Clin Oncol. 2008;26:1059-1065.
6. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481. (Pubitemid 29220854)
7. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer. 2000;89:111-117. (Pubitemid 30185917)
8. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21(suppl 2):S8-S15. (Pubitemid 351592775)
9. Allred DC. Commentary: hormone receptor testing in breast cancer: a distress signal from Canada. Oncologist. 2008;13:1134-1136.
10. Allison KH. Estrogen receptor expression in breast cancer: we cannot ignore the shades of gray. Am J Clin Pathol. 2008;130:853-854.
11. Goldstein NS, Ferkowicz M, Odish E, et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003; 120:86-92. (Pubitemid 37046374)
12. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134:e48-e72.
13. Hede K. Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. J Natl Cancer Inst. 2008;100: 836-837. 844.
14. Regan MM, Viale G, Mastropasqua MG, et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006;98:1571-1581. (Pubitemid 44680908)
15. Badve SS, Baehner FL, Gray RP, et al. Estrogen-and progesteronereceptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008;26:2473-2481.
16. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25:3846-3852. (Pubitemid 47477259)
17. Welsh AW, Moeder CB, Kumar S, et al. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol. 2011;29:2978-2984.
18. Rhodes A, Jasani B, Balaton AJ, et al. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol. 2000;53:292-301. (Pubitemid 30180402)
19. Francis GD, Dimech M, Giles L, et al. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. J Clin Pathol. 2007;60:1277-1283. (Pubitemid 350084552)
20. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-2795.
21. Barnes DM, Harris WH, Smith P, et al. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer. 1996;74:1445-1451. (Pubitemid 26370738)
22. Cheang MC, Treaba DO, Speers CH, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006;24:5637-5644. (Pubitemid 46631303)
23. Huang Z, Zhu W, Szekeres G, et al. Development of new rabbit monoclonal antibody to estrogen receptor: immunohistochemical assessment on formalin-fixed, paraffin-embedded tissue sections. Appl Immunohistochem Mol Morphol. 2005;13:91-95. (Pubitemid 40283809)
24. Rossi S, Laurino L, Furlanetto A, et al. Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol. 2005;124:295-302. (Pubitemid 41060143)
25. Brock JE, Hornick JL, Richardson AL, et al. A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results. Am J Clin Pathol. 2009;132:396-401.
26. Dolled-Filhart M, McCabe A, Giltnane J, et al. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 2006;66:5487-5494. (Pubitemid 43844977)
27. McCabe A, Dolled-Filhart M, Camp RL, et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst. 2005;97: 1808-1815. (Pubitemid 43033901)
28. Treaba DO, Hing AW, Tse CC, et al. Significantly improved sensitivity for ER detection in breast cancer using a new rabbit monoclonal anti-ER antibody (SP1). Mod Pathol. 2005;18:53A. (Poster presentation at 94th AnnualMeeting of the United States and Canadian Academy of Pathology, San Antonio, TX, February 2005).
29. Qiu J, Kulkarni S, Chandrasekhar R, et al. Effect of delayed formalin fixation on estrogen and progesterone receptors in breast cancer: a study of three different clones. Am J Clin Pathol. 2010;134:813-819.
30. Traish AM, al-Fadhli S, Klinge C, et al. Identification of structurally altered estrogen receptors in human breast cancer by site-directed monoclonal antibodies. Steroids. 1995;60:467-474.
31. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943-1949. (Pubitemid 32012762)
32. Gown AM, Barry TS, Kandalaft P, et al. A new anti-ER rabbit monoclonal antibody improves efficiency of immunohistochemical evaluation of ER status in breast cancer. Mod Pathol. 2005; 18(suppl 1):35A.